The DOI matches its Crossref record.
Acetazolamide in the Treatment of Seizures
Abstract
OBJECTIVE: TO summarize the pharmacology, pharmacokinetics, efficacy, and safety of acetazolamide and to evaluate its therapeutic role in patients with epilepsy. DATA SOURCES: A computerized search of the MEDLINE (OVID) database (1966–1994) was used to identify publications regarding acetazolamide. The MEDLINE search was supplemented by information from textbooks. STUDY SELECTION: Included were English-language review articles, clinical trials, cohort studies, and case reports. Topics investigated included basic pharmacology, therapeutics, toxicology, adverse reactions, dosage, administration, and pharmacokinetics of acetazolamide. DATA SYNTHESIS: Acetazolamide, a carbonic anhydrase inhibitor, has been approved for the treatment of epilepsy since 1953. Acetazolamide is primarily used in combination therapy with other antiepileptic medications in both children and adults although it may be used as monotherapy. Drug concentration monitoring has not been found to be routinely beneficial. Adverse effects include kidney stones, metabolic acidosis, lethargy, appetite suppression, paresthesias, and rare blood dyscrasias. Partial tolerance may develop to the antiepileptic activity. CONCLUSIONS: Acetazolamide is a beneficial adjunctive agent in the pharmacotherapy of epilepsy and should be considered in refractory epilepsy. Although it may be useful in partial, myoclonic, absence, and primary generalized tonic—clonic seizures uncontrolled by other marketed agents, acetazolamide has been inadequately studied by current standards and its use has been limited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Carbonic anhydrase inhibitors and their therapeutic potential
Supuran, C. T., & Scozzafava, A. (2000) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.10.5.575 · Cited by 549
Mechanisms of action of currently used antiseizure drugs
Sills, G. J., & Rogawski, M. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107966 · Cited by 489
Carbonic anhydrase inhibitors: Sulfonamides as antitumor agents?
Supuran, C. T., Briganti, F., Tilli, S., Chegwidden, W. R., & Scozzafava, A. (2001) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00288-1 · Cited by 277
Mishra, C. B., Tiwari, M., & Supuran, C. T. (2020) · Medicinal Research Reviews · doi:10.1002/med.21713 · Cited by 260
GABAA Receptors in Normal Development and Seizures: Friends or Foes?
Galanopoulou, A. (2008) · Current Neuropharmacology · doi:10.2174/157015908783769653 · Cited by 156
Metadata
- Authors
- Reiss, W. G., & Oles, K. S.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 1996-05
- Volume
- 30
- Issue
- 5
- Pages
- 514-519
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2156290068
- Cited by
- 182
- References
- 0
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acetazolamide in the Treatment of Seizures. https://app.cochat.ai/papers/10.1177/106002809603000515
- The paper
- Reiss, W. G., & Oles, K. S. (1996). Acetazolamide in the Treatment of Seizures. Annals of Pharmacotherapy. https://doi.org/10.1177/106002809603000515
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.